The forecasted trajectory is propelled by three macro‑drivers: a rising global prevalence of cardiac arrhythmias, an aging demographic that expands the procedural pool, and accelerating technology shifts such as high‑density mapping, AI‑enabled signal analytics, and integration with robotic catheter systems. Competitive intensity among incumbents—Medtronic, Abbott, Boston Scientific, and Biosense Webster—fuels continuous innovation, while evolving regulatory frameworks and expanding reimbursement pathways in key markets accelerate adoption. Geographically, North America remains the largest market, anchored by high procedure volumes and early technology uptake, whereas the Asia‑Pacific region is the fastest‑growing, driven by expanding hospital networks and increasing awareness of EP therapies across China, Japan, and India.